Dualyx raises €40 million to progress Treg therapies for autoimmune diseases into the clinic Use of proceeds will enable the development of the Company's lead autoimmune program DT-001, targeting
EQS-News: Andera Partners / Key word(s): Financing Andera Partners co-leads a €40 million Series A of Dualyx, a Belgian biotech developing novel Treg therapies for autoimmune diseases 15.05.2023
FIRE1, today announced the close of a $25 million financing round led by new investors Andera Partners and Novo Holdings, with participation and ongoing support from existing investors Gilde Healthcare